Pro Medicus Limited
Pro Medicus Limited (PME.AX) Stock Competitors & Peer Comparison
See (PME.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PME.AX | A$321.89 | +0.66% | 33.6B | 346.12 | A$0.93 | +0.15% |
| CGS.AX | A$1.73 | +0.87% | 293.7M | 24.71 | A$0.07 | N/A |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ONE.AX | A$0.25 | -2.00% | 185.7M | -8.17 | -A$0.03 | N/A |
| ALC.AX | A$0.12 | -4.17% | 154.4M | -11.50 | -A$0.01 | N/A |
| AYA.AX | A$1.02 | -2.86% | 116.7M | -5.69 | -A$0.18 | N/A |
| SHG.AX | A$0.30 | -4.76% | 90.5M | -15.00 | -A$0.02 | N/A |
| M7T.AX | A$0.38 | -2.56% | 89.3M | -19.00 | -A$0.02 | N/A |
| BMT.AX | A$0.25 | -7.55% | 71.2M | -12.25 | -A$0.02 | N/A |
| PCK.AX | A$0.04 | -7.89% | 64.5M | -3.50 | -A$0.01 | N/A |
Stock Comparison
PME.AX vs CGS.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, CGS.AX has a market cap of 293.7M. Regarding current trading prices, PME.AX is priced at A$321.89, while CGS.AX trades at A$1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas CGS.AX's P/E ratio is 24.71. In terms of profitability, PME.AX's ROE is +0.48%, compared to CGS.AX's ROE of +0.20%. Regarding short-term risk, PME.AX is less volatile compared to CGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check CGS.AX's competition here
PME.AX vs VHT.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, PME.AX is priced at A$321.89, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, PME.AX's ROE is +0.48%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, PME.AX is more volatile compared to VHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check VHT.AX's competition here
PME.AX vs ONE.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, ONE.AX has a market cap of 185.7M. Regarding current trading prices, PME.AX is priced at A$321.89, while ONE.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas ONE.AX's P/E ratio is -8.17. In terms of profitability, PME.AX's ROE is +0.48%, compared to ONE.AX's ROE of -1.17%. Regarding short-term risk, PME.AX is less volatile compared to ONE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check ONE.AX's competition here
PME.AX vs ALC.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, ALC.AX has a market cap of 154.4M. Regarding current trading prices, PME.AX is priced at A$321.89, while ALC.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas ALC.AX's P/E ratio is -11.50. In terms of profitability, PME.AX's ROE is +0.48%, compared to ALC.AX's ROE of -0.06%. Regarding short-term risk, PME.AX is less volatile compared to ALC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check ALC.AX's competition here
PME.AX vs AYA.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, AYA.AX has a market cap of 116.7M. Regarding current trading prices, PME.AX is priced at A$321.89, while AYA.AX trades at A$1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas AYA.AX's P/E ratio is -5.69. In terms of profitability, PME.AX's ROE is +0.48%, compared to AYA.AX's ROE of -0.92%. Regarding short-term risk, PME.AX is less volatile compared to AYA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check AYA.AX's competition here
PME.AX vs SHG.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, SHG.AX has a market cap of 90.5M. Regarding current trading prices, PME.AX is priced at A$321.89, while SHG.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas SHG.AX's P/E ratio is -15.00. In terms of profitability, PME.AX's ROE is +0.48%, compared to SHG.AX's ROE of -0.80%. Regarding short-term risk, PME.AX is less volatile compared to SHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check SHG.AX's competition here
PME.AX vs M7T.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, M7T.AX has a market cap of 89.3M. Regarding current trading prices, PME.AX is priced at A$321.89, while M7T.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas M7T.AX's P/E ratio is -19.00. In terms of profitability, PME.AX's ROE is +0.48%, compared to M7T.AX's ROE of -0.10%. Regarding short-term risk, PME.AX is less volatile compared to M7T.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check M7T.AX's competition here
PME.AX vs BMT.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, BMT.AX has a market cap of 71.2M. Regarding current trading prices, PME.AX is priced at A$321.89, while BMT.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas BMT.AX's P/E ratio is -12.25. In terms of profitability, PME.AX's ROE is +0.48%, compared to BMT.AX's ROE of -0.12%. Regarding short-term risk, PME.AX is less volatile compared to BMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check BMT.AX's competition here
PME.AX vs PCK.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, PCK.AX has a market cap of 64.5M. Regarding current trading prices, PME.AX is priced at A$321.89, while PCK.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas PCK.AX's P/E ratio is -3.50. In terms of profitability, PME.AX's ROE is +0.48%, compared to PCK.AX's ROE of -4.53%. Regarding short-term risk, PME.AX is less volatile compared to PCK.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check PCK.AX's competition here
PME.AX vs MDR.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, MDR.AX has a market cap of 46.9M. Regarding current trading prices, PME.AX is priced at A$321.89, while MDR.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas MDR.AX's P/E ratio is -7.50. In terms of profitability, PME.AX's ROE is +0.48%, compared to MDR.AX's ROE of -0.09%. Regarding short-term risk, PME.AX is less volatile compared to MDR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check MDR.AX's competition here
PME.AX vs DOC.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, DOC.AX has a market cap of 45.8M. Regarding current trading prices, PME.AX is priced at A$321.89, while DOC.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas DOC.AX's P/E ratio is -4.17. In terms of profitability, PME.AX's ROE is +0.48%, compared to DOC.AX's ROE of -5.56%. Regarding short-term risk, PME.AX is less volatile compared to DOC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check DOC.AX's competition here
PME.AX vs EMD.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, EMD.AX has a market cap of 30M. Regarding current trading prices, PME.AX is priced at A$321.89, while EMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas EMD.AX's P/E ratio is -1.63. In terms of profitability, PME.AX's ROE is +0.48%, compared to EMD.AX's ROE of -0.56%. Regarding short-term risk, PME.AX is less volatile compared to EMD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check EMD.AX's competition here
PME.AX vs COO.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, PME.AX is priced at A$321.89, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas COO.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.48%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, PME.AX is more volatile compared to COO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check COO.AX's competition here
PME.AX vs RHT.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, RHT.AX has a market cap of 17.5M. Regarding current trading prices, PME.AX is priced at A$321.89, while RHT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas RHT.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.48%, compared to RHT.AX's ROE of -0.03%. Regarding short-term risk, PME.AX is less volatile compared to RHT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check RHT.AX's competition here
PME.AX vs IME.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, IME.AX has a market cap of 16.1M. Regarding current trading prices, PME.AX is priced at A$321.89, while IME.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas IME.AX's P/E ratio is -5.00. In terms of profitability, PME.AX's ROE is +0.48%, compared to IME.AX's ROE of -0.18%. Regarding short-term risk, PME.AX is less volatile compared to IME.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check IME.AX's competition here
PME.AX vs 1ST.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, PME.AX is priced at A$321.89, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, PME.AX's ROE is +0.48%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, PME.AX is more volatile compared to 1ST.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check 1ST.AX's competition here
PME.AX vs HIQ.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, HIQ.AX has a market cap of 9.4M. Regarding current trading prices, PME.AX is priced at A$321.89, while HIQ.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas HIQ.AX's P/E ratio is -2.00. In terms of profitability, PME.AX's ROE is +0.48%, compared to HIQ.AX's ROE of +2.49%. Regarding short-term risk, PME.AX is more volatile compared to HIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check HIQ.AX's competition here
PME.AX vs ICR.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, ICR.AX has a market cap of 6.3M. Regarding current trading prices, PME.AX is priced at A$321.89, while ICR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas ICR.AX's P/E ratio is -1.30. In terms of profitability, PME.AX's ROE is +0.48%, compared to ICR.AX's ROE of -10.86%. Regarding short-term risk, PME.AX is more volatile compared to ICR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check ICR.AX's competition here
PME.AX vs OPL.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, OPL.AX has a market cap of 5.7M. Regarding current trading prices, PME.AX is priced at A$321.89, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas OPL.AX's P/E ratio is -2.30. In terms of profitability, PME.AX's ROE is +0.48%, compared to OPL.AX's ROE of +12.65%. Regarding short-term risk, PME.AX is less volatile compared to OPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check OPL.AX's competition here
PME.AX vs MEB.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, PME.AX is priced at A$321.89, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.48%, compared to MEB.AX's ROE of -0.47%. Regarding short-term risk, PME.AX is less volatile compared to MEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PME.AX.Check MEB.AX's competition here
PME.AX vs GLH.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, GLH.AX has a market cap of 4.5M. Regarding current trading prices, PME.AX is priced at A$321.89, while GLH.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas GLH.AX's P/E ratio is -7.60. In terms of profitability, PME.AX's ROE is +0.48%, compared to GLH.AX's ROE of +0.27%. Regarding short-term risk, PME.AX is more volatile compared to GLH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check GLH.AX's competition here
PME.AX vs TD1.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, TD1.AX has a market cap of 4.2M. Regarding current trading prices, PME.AX is priced at A$321.89, while TD1.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas TD1.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.48%, compared to TD1.AX's ROE of -0.24%. Regarding short-term risk, PME.AX is more volatile compared to TD1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check TD1.AX's competition here
PME.AX vs CTQ.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, CTQ.AX has a market cap of 2.8M. Regarding current trading prices, PME.AX is priced at A$321.89, while CTQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas CTQ.AX's P/E ratio is -1.20. In terms of profitability, PME.AX's ROE is +0.48%, compared to CTQ.AX's ROE of -0.62%. Regarding short-term risk, PME.AX is more volatile compared to CTQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check CTQ.AX's competition here
PME.AX vs OAK.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, OAK.AX has a market cap of 1.8M. Regarding current trading prices, PME.AX is priced at A$321.89, while OAK.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas OAK.AX's P/E ratio is -1.67. In terms of profitability, PME.AX's ROE is +0.48%, compared to OAK.AX's ROE of -0.44%. Regarding short-term risk, PME.AX is more volatile compared to OAK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check OAK.AX's competition here
PME.AX vs JTL.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, PME.AX is priced at A$321.89, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.48%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, PME.AX is more volatile compared to JTL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check JTL.AX's competition here
PME.AX vs TTB.AX Comparison July 2025
PME.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 33.6B. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, PME.AX is priced at A$321.89, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 346.12, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, PME.AX's ROE is +0.48%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, PME.AX is more volatile compared to TTB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PME.AX.Check TTB.AX's competition here